Indian biologics growth forecast despite setbacks, data shows

From time-to-time there are manufacturing woes at Indian biologics plants that grab headlines and set back development or production of a drug, but that has not stopped the country’s biologics market as a whole being set for robust growth this year.

That is a finding from research from CPhI showing that, despite these ongoing reputational challenges, there will be growth in the market, driven by biosimilars production.

The India specific findings from CPhI’s bio league tables predict strong ‘bio growth potential’ in India throughout 2019. In this category, India scored broadly level with the well-established advanced bio markets of Germany, Ireland and Japan, and behind only the USA – but significantly, ahead of China and its widely-documented rapidly expanding bio sector.